Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New Trials

28 Apr 2008 08:09

Plant Health Care PLC28 April 2008 For immediate release 28 APRIL 2008 PLANT HEATH CARE PLC ("Plant Heath Care" or "the Company") Plant Health Care, Inc. initiates large scale grower tests for a ProActTM + Glyphosate product Plant Heath Care, (AIM: PHC.L), a leading provider of natural products forplants and soil, has initiated a large scale field trial program for corn,soybeans, and cotton to further evaluate the already established benefits ofusing ProActTM in combination with glyphosate, the world's most commonly usedherbicide, when applied over-the-top of glyphosate resistant crops. Five yearsof independent testing have demonstrated significant yield increases in cottonand corn when treated with a combination of ProAct and glyphosate. ProAct is afoliar spray product for reducing nematode populations and improving overallplant health. ProAct, which is the only foliar spray product labeled for useagainst nematodes in corn and soybeans, contains Harpin, a second generationharpin protein formulated as a wettable dry granule. PHC Director of Field Biology Ned French says, "ProAct increases yields. Thecomprehensive data from multi-year ProAct research shows average increases of2.5 bushels/acre in soybeans, 7 bushels/acre in corn, and 68 pounds of cottonlint/acre. These yield increases translate into economic returns of $28, $35,and $50/acre, respectively. The ProAct + Glyphosate Program will help bothgroups learn more about the benefits in real-world farming conditions." All participants will be asked to join a series of post-harvest teleconferencesto discuss how the ProAct + glyphosate tank-mix performed on their farms. PHCwill use the information gleaned from the teleconferences as the basis forbetter understanding farmer needs and perceptions as they relate to the use ofProAct + glyphosate. PHC, started in 1995, was originally focused on horticulture, turf, vegetablesand high value crops. The company started targeting field crops -corn, soybeans,and cotton - in 2007 based on its acquisition of harpin protein technologyproducts such as ProAct. ProAct contains the most recently developed andeffective generation of harpin proteins. Plant Health Care, Inc., headquartered in Pittsburgh, PA, is a wholly ownedsubsidiary of Plant Health Care plc (AIM:PHC), a leading provider of naturalproducts for plants and soil. PHC has operations in the United States, Mexico,the United Kingdom, Spain, and the Netherlands. PHC products are used in theagriculture, landscape, horticulture and land reclamation industries and areenvironmentally beneficial. Through the commercialization of these products, PHCis capitalizing on current long-term trends toward natural systems andbiological products for plant care and soil and water management. For moreinformation and complete details pertaining to the ProAct SatisfactionGuarantee, go to www.planthealthcare.com. -ends- For further information: Plant Heath Care plc John Brady, Chief Executive Tel: 001 603 525 3702 Evolution Securities Limited Tim Worlledge/ Tim Redfern Tel: 020 7071 4300 Tavistock Communications Jeremy Carey/Matt Ridsdale Tel: 020 7920 3150 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.